Merck Serono Europe informed the European Medicines Agency that it was withdrawing its marketing authorization application for oral cladribine (Movectro), 10-mg tablets, intended for the treatment of relapsing-remitting multiple sclerosis.
Merck Serono Europe informed the European Medicines Agency (EMA) that it was withdrawing its marketing authorization application for oral cladribine (Movectro), 10-mg tablets, intended for the treatment of relapsing-remitting multiple sclerosis.
In its official letter, the company stated that its decision to withdraw the application was based on the EMA’s Committee for Medicinal Products for Human Use’s (CHMP) negative opinion of the data available to date, reported Medical News Today. The CHMP is responsible for preparing the EMA’s opinions on all questions concerning medicines for human use.
“Movectro was regarded to be a key launch candidate for the German company-with the orally active drug consolidating its already strong multiple sclerosis therapy reputation in the United States, as Merck Serono-along with Pfizer- markets the blockbuster interferon therapy Rebif [interferon beta-1a] in the United States,” John Bird, senior analyst, at Datamonitor Healthcare, told Formulary.
According to Bird, if Merck KGaA decides to withdraw Movectro from the U. S. regulatory process, the company forfeits forecasted sales of $350 million by 2015 for this region, alone.
It has been reported that FDA will complete its review of the drug by February 28. Meanwhile, Novartis’ Gilenya (fingolimod 0.5 mg) won FDA approval last year for the treatment of relapsing forms of MS.
“Failure to gain FDA approval for Movectro in the United States will further enhance Novartis’ position in the lucrative oral MS market,” Bird said.
According to the EMA’s CHMP website, in September 2010, the CHMP had concerns about Movectro’s safety. An increased number of patients with cancer were observed in clinical trials with Movectro compared to the control group. The CHMP also noted that the benefits and the most appropriate dosage for treatment had not been fully established in patients who were expected to use the medicine. Therefore, at that time, the CHMP said that the benefits of Movectro did not outweigh its risks and recommended refusal of marketing authorization. In January 2011, the CHMP’s main concerns were not resolved during the re-examination procedure. In particular, it was still concerned about Movectro’s long-term safety, even if it were to be used in the restricted group of patients. Therefore the Committee confirmed its initial negative opinion.
Merck Serono Europe told CHMP that it intends to continue clinical trials with Movectro, which so far has only been approved in Australia and Russia.
According to the National Multiple Sclerosis Society, approximately 400,000 Americans have MS, and every week about 200 people are diagnosed. MS affects about 2.5 million people worlwide.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.